clinical trials
4 stories filed under clinical trials on Beyond Market Intelligence. The newest of them: “AI Biotech Enveda Accelerates Drug Development with $311M Investment”, “Why open data, not moats, will let AI engineer better medicine”, and “Discover how better data unlocks AI's real potential in healthcare.”. Enveda's $311M raise isn't just a big number; it's a signal that AI-driven drug discovery is moving from promise to pipeline. Vijay Pande walked away from managing $4 billion at a16z to bet smaller, and that restraint is exactly the point. Acme AI is the next-generation, AI-powered spreadsheet platform built to replace Excel and redefine how analysts, data scientists, and enterprise teams work… The list below is every clinical trials story on Beyond Market Intelligence, newest first.
AI Biotech Enveda Accelerates Drug Development with $311M Investment
Enveda's $311M raise isn't just a big number; it's a signal that AI-driven drug discovery is moving from promise to pipeline. The $2B valuation reflects real momentum, especially as the company targets skin conditions and tackles the stubborn problem of weight regain after GLP-1s. That's practical science with tangible outcomes. We're watching a biotech that understands the patient's journey, not just the lab bench. For more on who's betting big on emerging tech, check our piece on Wahlberg and Lee's upcoming Disrupt discussion.
Why open data, not moats, will let AI engineer better medicine
Vijay Pande walked away from managing $4 billion at a16z to bet smaller, and that restraint is exactly the point. His new firm, VZVC, leans into AI-native investing because he sees biology shifting from discovery to engineering. Clinical trials remain brutally expensive, and he argues open, shared datasets will matter more than proprietary walls. That conviction feels right. For a deeper look at how AI handles messy real-world data, our piece on real-world computer vision deployments is worth reading.
Discover how better data unlocks AI's real potential in healthcare.
If AI is going to move the needle on cancer, it won't be through clever algorithms alone. This startup argues the real bottleneck is data, plain and simple. That's a refreshingly grounded take in a field prone to hype. We're not talking about magic; we're talking about feeding models the right, clean information. It's a messier problem than most want to admit, but it's the one that matters.
How 37,000 AI agents collaborate to transform drug discovery
The assumption that one engineer equals one AI agent is already outdated. At Stanford, James Zou's team has scaled past that model, building a virtual biotech where 37,000 specialized agents collaborate like a real company. The results speak for themselves: the system designed a drug that Merck later independently validated, earning FDA breakthrough status. For developers, the lesson isn't about building smarter single agents, it's about designing environments where thousands can work together. That's a shift worth exploring, especially as orchestration becomes the real bottleneck.